Chuanxu Luo1, Xiaorong Zhong1, Ling Deng1, Yuxin Xie1, Kejia Hu1, Hong Zheng2. 1. Laboratory of Molecular Diagnosis of Cancer & Breast Medical Oncology, Clinical Research Center for Breast, West China Hospital, Sichuan University, Chengdu, China. 2. Laboratory of Molecular Diagnosis of Cancer & Breast Medical Oncology, Clinical Research Center for Breast, West China Hospital, Sichuan University, Chengdu, China. Electronic address: hzheng@scu.edu.cn.
Abstract
PURPOSE: Postmastectomy radiation therapy (PMRT) had heterogeneous effects on survival outcome of patients with T1-2N1 breast cancer. A reliable model to estimate individuals' risk of locoregional recurrence (LRR) and the potential benefit derived from PMRT is needed. METHODS AND MATERIALS: We retrospectively analyzed 1141 patients with T1-2N1 breast cancer who underwent mastectomy between January 2001 and December 2012. Based on the Fine and Gray competing risks regression in 623 unirradiated patients, a nomogram predicting LRR was conducted for risk quantification. Decision tree analysis was performed for patient grouping. The impact of PMRT was evaluated among 3 subgroups. RESULTS: With a median follow-up of 74.9 months, the 5-year cumulative incidence of LRR, distant recurrence (DR) and breast cancer mortality (BCM) were 3.9%, 8.8%, and 6.0%, respectively, for the entire cohort. Based on nomogram scores, patients were classified into 3 risk groups in decision tree analysis. In the high-risk group, PMRT was found to be associated with a 12.7% risk reduction of 5-year LRR, 9.2% risk reduction of 5-year DR, and 7.0% risk reduction of 5-year BCM, whereas it was not significantly associated with LRR, DR, or BCM in low- and intermediate-risk groups. CONCLUSIONS: The nomogram performed individualized risk quantification of LRR in patients with T1-2N1 breast cancer. A newly identified patient subgroup with high risk of LRR were found to derive survival benefit from PMRT.
PURPOSE: Postmastectomy radiation therapy (PMRT) had heterogeneous effects on survival outcome of patients with T1-2N1 breast cancer. A reliable model to estimate individuals' risk of locoregional recurrence (LRR) and the potential benefit derived from PMRT is needed. METHODS AND MATERIALS: We retrospectively analyzed 1141 patients with T1-2N1 breast cancer who underwent mastectomy between January 2001 and December 2012. Based on the Fine and Gray competing risks regression in 623 unirradiated patients, a nomogram predicting LRR was conducted for risk quantification. Decision tree analysis was performed for patient grouping. The impact of PMRT was evaluated among 3 subgroups. RESULTS: With a median follow-up of 74.9 months, the 5-year cumulative incidence of LRR, distant recurrence (DR) and breast cancer mortality (BCM) were 3.9%, 8.8%, and 6.0%, respectively, for the entire cohort. Based on nomogram scores, patients were classified into 3 risk groups in decision tree analysis. In the high-risk group, PMRT was found to be associated with a 12.7% risk reduction of 5-year LRR, 9.2% risk reduction of 5-year DR, and 7.0% risk reduction of 5-year BCM, whereas it was not significantly associated with LRR, DR, or BCM in low- and intermediate-risk groups. CONCLUSIONS: The nomogram performed individualized risk quantification of LRR in patients with T1-2N1 breast cancer. A newly identified patient subgroup with high risk of LRR were found to derive survival benefit from PMRT.
Authors: Maria Cristina Leonardi; Ida Rosalia Scognamiglio; Barbara Alicja Jereczek-Fossa; Giovanni Corso; Patrick Maisonneuve; Samantha Dicuonzo; Damaris Patricia Rojas; Maria Alessia Zerella; Anna Morra; Marianna Alessandra Gerardi; Mattia Zaffaroni; Alessandra De Scalzi; Antonia Girardi; Francesca Magnoni; Emilia Montagna; Cristiana Iuliana Fodor; Viviana Enrica Galimberti; Paolo Veronesi; Roberto Orecchia; Roberto Pacelli Journal: Breast Cancer Res Treat Date: 2021-04-27 Impact factor: 4.872
Authors: Huiyang Li; Kirellos Said Abbas; Basel Abdelazeem; Yao Xu; Yile Lin; Haixiao Wu; Vladimir P Chekhonin; Karl Peltzer; Chao Zhang Journal: Front Oncol Date: 2022-02-25 Impact factor: 6.244
Authors: Sarah M C Sittenfeld; Emily C Zabor; Sarah N Hamilton; Henry M Kuerer; Mahmoud El-Tamer; George E Naoum; Pauline T Truong; Alan Nichol; Benjamin D Smith; Wendy A Woodward; Tracy-Ann Moo; Simon N Powell; Chirag S Shah; Alphonse G Taghian; Ibrahim Abu-Gheida; Rahul D Tendulkar Journal: Cancer Date: 2022-06-17 Impact factor: 6.921